How Effective Is Tremfya for Psoriatic Arthritis?
Tremfya (guselkumab), an IL-23 inhibitor from Janssen, shows strong efficacy in treating active psoriatic arthritis (PsA) in adults. In phase 3 trials like DISCOVER-1 and DISCOVER-2, 59-73% of patients achieved ACR20 response (20% improvement in American College of Rheumatology criteria) at week 24, compared to 20-22% on placebo.[1][2] ACR50 and ACR70 responses reached 40-50% and 20-30%, respectively, by week 24, with benefits sustained through 2 years.[3]
Subcutaneous dosing every 8 weeks after initial loads provides rapid onset, with some improvements by week 4. It reduces joint pain, swelling, enthesitis, dactylitis, and skin psoriasis, plus inhibits radiographic joint damage progression (89-91% with minimal progression at 2 years).[1][4]
Who Responds Best and What Do Real-World Studies Show?
Bio-naive patients (no prior biologics) respond better: 80% ACR20 at week 24 vs. 60% in biologic-experienced.[2] Real-world data from registries like CorEvitas confirm 50-70% low disease activity by 12 months, aligning with trials.[5] About 20-30% achieve drug-free remission after 1-2 years, though most need ongoing therapy.
How Does Tremfya Stack Up Against Other PsA Treatments?
| Treatment | ACR20 at Week 24 | Skin Clearance (PASI90) | Joint Damage Inhibition |
|-----------|-------------------|--------------------------|------------------------|
| Tremfya | 59-73% | 60-70% | 89-91% |
| Cosentyx (secukinumab, IL-17) | 50-62% | 50-60% | 84% |
| Stelara (ustekinumab, IL-12/23) | 44-51% | 40-50% | 80% |
| Enbrel (etanercept, TNF) | 50-60% | 30-40% | 75-85% |
Tremfya excels in skin-joint synergy for psoriasis-dominant PsA, outperforming TNFs in skin clearance but matching on joints. Switchers from TNFs see 50-60% ACR20.[6][7] No head-to-head vs. JAK inhibitors like Xeljanz.
When Do Patients See Results and How Long Do They Last?
Joint improvements start week 4 (40% ACR20), peak at week 24, and hold through 5 years in extensions (70% ACR50).[3] Skin clears faster in psoriasis-PsA overlap. Long-term data: 60-80% retain response at 3 years; 10-20% discontinue yearly for loss of efficacy.[4]
What If It Doesn't Work or Side Effects Hit?
Primary non-response: 20-30% by week 24. Dose escalation or switching to IL-17 (e.g., Cosentyx) yields 40-50% recapture.[8] Common side effects (10-20%): upper respiratory infections, headache; serious (1-2%): infections, IBD flares. No increased MACE risk vs. placebo.[1] Monitor for TB reactivation.
Is Tremfya Approved and What's the Cost?
FDA-approved for PsA since 2020 (post-plaque psoriasis in 2017). List price ~$6,500/month (U.S.), but copay cards drop patient cost to $5-0 with insurance.[9] Patents extend to 2032-2033; no biosimilars yet.[10]
[1]: NEJM DISCOVER-1
[2]: Lancet DISCOVER-2
[3]: Ann Rheum Dis 2-year data
[4]: RMD Open 5-year
[5]: CorEvitas PsA Registry
[6]: Rheumatology Oxford comparison
[7]: J Drugs Dermatol switch data
[8]: Arthritis Res Ther non-response
[9]: GoodRx pricing
[10]: DrugPatentWatch Tremfya